TEVA vs VTRS vs RDY Stock Comparison

Teva Pharmaceutical Industries, Viatris and Dr Reddys Laboratories Prices as of Oct 29, 2026 Peers: Industry group
1 more company in this comparison (AMPH) Create a free account to keep reading and compare up to 10 companies.
VTRS Viatris Inc
$19.20 +6.0% 1M +87.0% 1Y
Market cap
$22.05B
P/E
–
Revenue (TTM)
$14.74B
Div. yield
2.50%
Generic Drugs Healthcare
4 wins

Head to Head

12 decided of 12

Teva Pharmaceutical Industries leads on 4 of the 12 questions below (Teva Pharmaceutical Industries 4, Dr Reddys Laboratories 4, Viatris 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionTEVAVTRSRDYLeader
Larger companyMarket capitalisation $48.32B $22.05B $11.78B TEVA
Cheaper on earningsLower P/E, profitable companies only 68.4x -54.4x 32.3x RDY
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.6x 7.3x 29.4x VTRS
Faster revenue growthRevenue growth, trailing twelve months +4.1% +4.4% -10.5% VTRS
More profitableNet margin, trailing twelve months 4.1% -2.8% 10.2% RDY
Better return on capitalReturn on invested capital 6.4% -0.2% 5.6% TEVA
Less leveragedLower net debt / EBITDA 5.0x 4.6x 1.2x RDY
Higher dividend yieldTrailing dividend yield 0.00% 2.50% 0.57% VTRS
Better 1-year returnPrice return, last 12 months +105.0% +87.0% +5.2% TEVA
Better 5-year returnAnnualised price return, 5 years +36.6%/yr +7.5%/yr +2.8%/yr TEVA
Less volatileAnnualised volatility, 1 year 38.0% 32.4% 26.3% RDY
Higher overall scoreMean of the five percentile scores vs peers 66/100 66/100 58/100 VTRS

Percentile Scorecard

TEVAVTRSRDY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisTEVAVTRSRDY
Valuation 83 #105 of 624 93 #42 of 624 91 #59 of 624
Growth 83 #102 of 601 49 #308 of 601 10 #541 of 601
Profitability 85 #80 of 541 82 #100 of 541 83 #93 of 541
Financial Health 11 #577 of 647 22 #502 of 647 43 #368 of 647
Shareholder Returns – 85 #54 of 359 62 #139 of 359
Overall 66 66 58
  • TEVA ranked among 671 companies in Pharmaceuticals and Biotechnology
  • VTRS ranked among 671 companies in Pharmaceuticals and Biotechnology
  • RDY ranked among 671 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodTEVAVTRSRDYSPY
1 month +4.2%+6.0%+9.8% +0.7%
3 months +17.2%+8.1%+19.2% +3.7%
6 months +18.2%+28.5%+3.4% +7.1%
Year to date +32.9%+54.2%+0.5% +12.8%
1 year +105.0%+87.0%+5.2% +11.9%
3 years +385.0%+117.2%+8.9% +85.2%
3 years, per year +69.3%+29.5%+2.9% +22.8%
5 years +374.5%+43.8%+14.8% +67.6%
5 years, per year +36.6%+7.5%+2.8% +10.9%
10 years -2.0%-48.4%+42.1% +262.0%
10 years, per year -0.2%-6.4%+3.6% +13.7%

Risk

MeasureTEVAVTRSRDYSPY
Volatility, 1Y 38.0%32.4%26.3% 12.7%
Downside volatility, 1Y 27.2%29.8%27.7% 12.6%
Beta vs S&P 500, 1Y 0.730.700.28 1.00
Return / volatility, 1Y 2.762.690.20 0.94
Max drawdown, 5Y -43.7%-52.9%-32.3% -25.4%
From 52-week high 0.0%0.0%-8.3% -1.2%
52-week high $41.49$19.20$15.38 $779.14
52-week low $20.03$10.11$11.40 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleTEVAVTRSRDY
P/E now vs peer median 68.4xmedian 17.8x -54.4xmedian 17.8x 32.3xmedian 17.8x
P/S now vs peer median 2.8xmedian 9.1x 1.5xmedian 9.1x 3.3xmedian 9.1x
EV/EBITDA now vs peer median 23.6xmedian 15.0x 12.7xmedian 15.0x 23.4xmedian 15.0x
P/FCF now vs peer median 35.8xmedian 21.7x 11.3xmedian 21.7x 843.8xmedian 21.7x
P/B now vs peer median 6.2xmedian 2.2x 1.5xmedian 2.2x 2.9xmedian 2.2x
PEG now vs peer median 2.15median 0.35 1.78median 0.35 -1.52median 0.35

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsTEVAVTRSRDY
Revenue $17.32B $14.74B $3.56B
Gross profit $9.09B $5.13B $1.76B
Operating income $1.60B -$87.30M $347.04M
Net income $708.00M -$410.70M $299.19M
Free cash flow $1.35B $1.95B $13.96M
R&D $1.72B $1.02B $244.48M
EPS (diluted) $0.61 $-0.35 $0.44
Cash & equivalents $3.66B $886.50M $138.41M
Total debt $16.59B $13.35B $752.59M
Shares (diluted) 1.17B 1.16B 833.33M
Enterprise value $35.17B $17.06B $11.15B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricTEVAVTRSRDY
P/E 68.4x -54.4x 32.3x
P/FCF 35.8x 11.3x 843.8x
P/Operating cash flow 25.5x 9.5x 34.6x
P/S 2.8x 1.5x 3.3x
P/B 6.2x 1.5x 2.9x
P/Tangible book 11.2x 37.8x 4.0x
EV/EBITDA 23.6x 12.7x 23.4x
EV/EBIT 38.2x -395.4x 35.7x
EV/Revenue 3.5x 2.3x 3.5x
EV/FCF 45.4x 17.7x 887.8x
EV/Operating cash flow 32.3x 14.8x 36.4x
PEG (3Y EPS CAGR) 2.15 1.78 -1.52

Growth

14 metrics
MetricTEVAVTRSRDY
Revenue growth (1Y) 4.1% 4.4% -10.5%
Revenue CAGR (3Y) 4.9% -1.9% 3.2%
Gross profit growth (1Y) 10.1% -0.7% -21.5%
Gross profit CAGR (3Y) 10.0% -6.0% -2.3%
Operating income growth (1Y) 79.3% 96.6% -58.2%
Operating income CAGR (3Y) 49.7% -27.6% -24.1%
Net income growth (1Y) 438.8% 88.2% -55.9%
Net income CAGR (3Y) 31.8% -30.5% -21.5%
EPS growth (1Y) 545.3% 88.1% -54.1%
EPS CAGR (3Y) 31.8% -30.6% -21.3%
Operating cash flow growth (1Y) 36.5% 12.9% -39.6%
Operating cash flow CAGR (3Y) 3.8% -3.0% -27.1%
Free cash flow growth (1Y) 51.5% 11.6% -98.4%
Free cash flow CAGR (3Y) 4.7% -3.6% -73.6%

Profitability

14 metrics
MetricTEVAVTRSRDY
Gross margin 52.5% 34.8% 49.5%
EBITDA margin 15.0% 18.4% 14.9%
Operating margin 9.3% -0.6% 9.7%
Pretax margin 4.1% -4.5% 10.7%
Net margin 4.1% -2.8% 10.2%
FCF margin 7.8% 13.3% 0.4%
Operating cash flow margin 11.0% 15.8% 9.5%
Return on equity 8.9% -2.8% 7.4%
Return on assets 1.8% -1.1% 5.0%
Return on invested capital 6.4% -0.2% 5.6%
Return on capital employed 6.6% -0.3% 7.9%
Asset turnover 0.4x 0.4x 0.6x
Cash conversion (OCF / net income) 2.7x -5.7x 1.1x
Stock comp / revenue 1.0% 1.2% 0.1%

Financial Health

11 metrics
MetricTEVAVTRSRDY
Debt / assets 41.6% 38.1% 12.6%
Debt / equity 2.1x 0.9x 0.2x
Net debt / EBITDA 5.0x 4.6x 1.2x
Debt / FCF 12.3x 6.8x 53.9x
Liabilities / assets 80.5% 59.3% 32.2%
Equity / assets 19.5% 40.7% 67.8%
Interest coverage – -0.2x 7.2x
Current ratio 0.9x 1.6x 1.9x
Quick ratio 0.5x 0.7x 0.7x
Cash ratio 0.2x 0.1x 0.1x
Altman Z-score 0.92 1.16 5.63

Shareholder Returns

7 metrics
MetricTEVAVTRSRDY
Dividend yield – 2.5% 0.6%
Net buyback yield – 1.4% -0.1%
Shareholder yield 0.0% 3.9% 0.5%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusTEVAVTRSRDY
Forward P/E 21.6xFY2026 7.3xFY2026 29.4xFY2026
EPS, next fiscal year $1.92FY2026 $2.62FY2026 $0.48FY2026
EPS growth, next FY -32.6%FY2026 +11.5%FY2026 -11.1%FY2026
EPS growth, the year after +66.1% -1.5% +20.8%
Revenue, next fiscal year $15.65BFY2026 $15.31BFY2026 $3.82BFY2026
Revenue growth, next FY -6.7%FY2026 +7.0%FY2026 +8.7%FY2026
Revenue growth, the year after +17.0% -4.8% +3.7%
TEVA estimates →VTRS estimates →RDY estimates →

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersTEVAVTRSRDY
Held by institutions 62.7% 89.9% 15.1%
Institutions holding 671 1,030 239
Change in shares held, QoQ +8.6% +5.6% +4.3%
Institutions buying 359 488 108
Institutions selling 191 318 97
Buyers to sellers 1.88 1.53 1.11
TEVA holders →VTRS holders →RDY holders →

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

TEVAVTRSRDY
TEVA 1.00 0.35 0.23
VTRS 0.35 1.00 0.27
RDY 0.23 0.27 1.00

Add a Peer

Largest companies in the same industry
TEVA · Generic Drugs
+AMRXAmneal Pharmaceuticals +BHCBausch Health Companies +ANIPAni Pharmaceuticals +ALVOAlvotech +AMPHAmphastar Pharmaceuticals +FENCFennec Pharmaceuticals +ELTPElite Pharmaceuticals +NTRBNutriBand
Plot all 42 Generic Drugs stocks →

Related Comparisons

TEVA vs AMRXAmneal Pharmaceuticals TEVA vs BHCBausch Health Companies TEVA vs ANIPAni Pharmaceuticals TEVA vs ALVOAlvotech

Frequently Asked Questions

Which is bigger, TEVA, VTRS and RDY?

Teva Pharmaceutical Industries (TEVA) is the largest by market capitalisation: Teva Pharmaceutical Industries (TEVA) $48.32B, Viatris (VTRS) $22.05B, Dr Reddys Laboratories (RDY) $11.78B.

Which stock is cheaper, TEVA, VTRS and RDY?

Dr Reddys Laboratories (RDY) trades on the lowest price-to-earnings ratio (Teva Pharmaceutical Industries (TEVA) 68.4x, Viatris (VTRS) -54.4x, Dr Reddys Laboratories (RDY) 32.3x). On next year's consensus earnings, Viatris (VTRS) is cheapest (Teva Pharmaceutical Industries (TEVA) 21.6x, Viatris (VTRS) 7.3x, Dr Reddys Laboratories (RDY) 29.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Viatris (VTRS) grew revenue fastest over the trailing twelve months: Teva Pharmaceutical Industries (TEVA) +4.1%, Viatris (VTRS) +4.4%, Dr Reddys Laboratories (RDY) -10.5%.

Which company is more profitable?

Dr Reddys Laboratories (RDY) has the highest net margin (Teva Pharmaceutical Industries (TEVA) 4.1%, Viatris (VTRS) -2.8%, Dr Reddys Laboratories (RDY) 10.2%). On return on invested capital, Teva Pharmaceutical Industries (TEVA) leads (Teva Pharmaceutical Industries (TEVA) 6.4%, Viatris (VTRS) -0.2%, Dr Reddys Laboratories (RDY) 5.6%).

Which stock has performed better?

Over the past year Teva Pharmaceutical Industries (TEVA) returned the most: Teva Pharmaceutical Industries (TEVA) +105.0%, Viatris (VTRS) +87.0%, Dr Reddys Laboratories (RDY) +5.2%. Over five years, Teva Pharmaceutical Industries (TEVA) compounded fastest (Teva Pharmaceutical Industries (TEVA) +36.6%/yr, Viatris (VTRS) +7.5%/yr, Dr Reddys Laboratories (RDY) +2.8%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Viatris (VTRS) has the highest dividend yield: Teva Pharmaceutical Industries (TEVA) 0.00%, Viatris (VTRS) 2.50%, Dr Reddys Laboratories (RDY) 0.57%. Teva Pharmaceutical Industries (TEVA) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Dr Reddys Laboratories (RDY) has been the steadiest (Teva Pharmaceutical Industries (TEVA) 38.0%, Viatris (VTRS) 32.4%, Dr Reddys Laboratories (RDY) 26.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, TEVA, VTRS and RDY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Teva Pharmaceutical Industries (TEVA) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.